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Abstract
Background: Patients with HIV infection are at risk of co-infection with HBV, as the routes of transmission are
shared and thus immunization with HBV vaccine could be protective in them. The aim of the present study was
to assess the efficacy of recombinant vaccine in treatment-naive HIV positive patients and healthy controls, and
to dissect out differences if any, in different limbs of immune response.
Methods: Forty HIV positive patients and 20 HIV negative controls, negative for HBsAg, HBsAbs and HBcAbs
were vaccinated with three doses of 40μg and 20μg of vaccine respectively. Patients were divided into high CD4
and low CD4 group based on CD4+ lymphocytes of 200 and < 200/mm3 respectively. Group II consisted of
healthy controls. Detection of phenotypic markers was done by flowcytometry. Cytokine estimation was done
by sandwich ELISA. HBsAbs were estimated in serum by ELISA.
Results: After vaccination, CD4+, CD8+ and CD3+ cells increased significantly in all the groups. There was no
increase in NK cell activity in patients with high CD4+ lymphocytes and only a marginal increase in patients with
low CD4+ lymphocytes (170 to 293/mm3) whereas a marked increase was observed in controls (252 to 490/
mm3). After vaccination, although an increase in memory cells was observed in HIV positive patients, yet HBsAb
levels were significantly lower than controls (P < 0.05) indicating a functional defect of memory cells in HIV/AIDS
patients. Basal IFN-γ levels were also significantly lower in HIV/AIDS patients (P < 0.01). Although the levels
increased after vaccination, the peak level remained lower than in controls. HBsAb titers were much lower in HIV
positive patients compared to controls. (High CD4+ group: 8834 mIU/ml, low CD4+ group: 462 mIU/ml Vs.
Controls: 16,906 mIU/ml). IL-4 and IL-10 were low in patients.
Conclusion: Despite a double dose in patients, IL-4 and IL-10, which regulate antibody response, were also
lower in patients, and this together with low CD4+ counts and lack of T help, accounted for low HBsAb levels.
Vaccination in patients with CD4+ lymphocytes < 50/mm3 was ineffective. Thus early immunization is advocated
in all HIV positive patients at a stage when they are still capable of mounting an adequate immune response
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Background
By the end of year 2004 nearly 5.1 million people were liv-
ing with HIV/AIDS in India [1]. Patients with HIV infec-
tion are frequently co-infected with hepatitis B virus
(HBV) as routes of transmission are shared. The preva-
lence of HBV co-infection depends on the prevailing risk
factor for acquiring infection in a given population e.g.,
Out of 30 HIV positive homosexuals from Maryland USA,
23 were positive for HBsAbs, 24 for antiHBc and only
three patients were negative for all the hepatitis B markers
[2]. A preliminary study at our institute documented
HBcAbs in 22 out of 80 patients, 6 were HBsAg positive
and four patients had evidence of replicating virus [3].
Acute hepatitis caused by HBV is milder in HIV infected
patients but chronic disease is more frequent with a
poorer prognosis and increased infectivity [4]. Patients
who have HIV before their HBV infections are more likely
to become HBsAg carriers. On the other hand, prior HBV
infection is unlikely to be specifically associated either
with acquisition of HIV infection or increased rate of pro-
gression [5]. The development of HBV vaccines has
offered new strategies for protecting these high-risk
groups. There are conflicting reports of antibody response
against HBV vaccine in HIV positive patients depending
upon the stage of the disease.
Although substantial literature is available regarding anti-
body response to different HBV vaccines in Caucasians,
yet precise events pertaining to cellular immune
responses, which are crucial for an optimal immune
response are either sparse or their correlation with anti-
body response is imperfect. Further, since immune
responses are linked to environmental, genetic and nutri-
tional factors, these are likely to vary in different geo-
graphical areas in different clades and different
population groups. Thus, data obtained from the western
countries cannot be reliably extrapolated to Indian popu-
lation. The present study was aimed to assess the efficacy
of an indigenous HBV vaccine in HIV positive patients
harboring mainly clade C [6] and to study the different
cell populations with their functional attributes especially
in relation to HBsAb formation. An insight into various
cellular subsets and immune aberrations in HIV positive
patients in response to HBV vaccination are expected to
give valuable leads for better planning and evaluation of
other vaccines which may be required in a rapidly expand-
ing HIV infected population.
Methods
Diagnosis of HIV was established as per National AIDS
Control Organization (NACO) guidelines (WHO criteria
adopted by NACO) [7]. HIV infected, asymptomatic
patients attending special medical out patient department
of PGIMER, Chandigarh (India) were enrolled in the
study. These patients could not afford Highly Active Anti-
Retroviral Treatment (HAART). Control subjects were
recruited from the healthy HIV negative hospital staff.
Written consent was obtained and trained counselors per-
formed pre-test counseling.
HIV infected patients and controls were screened for
HBsAg and HBsAb by ELISA using Monalisa HBsAg and
Monalisa antiHBs 3.0 kits (Sanofi Diagnostics, Pasture).
Subjects positive for HBsAg, HBsAb and HBcAb were
excluded from the study. A total of 40 asymptomatic HIV
positive patients and 20 control subjects were included in
the vaccination and immune assessment study under 2
groups. HIV positive patients were subdivided into two
groups on the basis of their CD4
+ lymphocytes, group IA,
high CD4 group with an absolute CD4
+ lymphocyte count
of ≥ 200/mm3 and group 1B, low CD4 group with an abso-
lute CD4
+ lymphocyte count of < 200/mm3. Group II con-
sisted of 20 normal healthy control subjects.
Vaccine dosage and administration
All the patients and controls received three doses of
recombinant Senvac™ HBV vaccine (Shanta Biotechnics,
Hyderabad) in the deltoid region at 0, 1 and 6 months. All
HIV positive patients were given 40 μg (double dose) of
vaccine in each dose, while controls subjects received 20
μg (usual dose) of vaccine.
Immune assessment
Phenotypic characterization of immune cells was done by
flowcytometry on EDTA blood using FACSCAN flowcy-
tometer with cell quest software (Becton Dickinson,
Immunoflowcytometry System. San Jose, CA, USA). CD4
+
and CD8
+ lymphocytes (helper/cytotoxic) were studied
using Simultest CD4/CD8 monoclonal antibodies conju-
gated with fluorescein isothiocyanate (FITC)/phycoeryth-
rin (PE) respectively. CD3
+ T cells (pan-T cell) and CD16+56
NK (natural killer) cells were studied using Simultest CD3
-FITC, CD16+56 -PE monoclonal antibodies. Naïve T lym-
phocytes were studied using CD45RA-FITC monoclonal
antibodies and memory cells were enumerated using
CD45RO -PE monoclonal antibodies. The samples for flow-
cytometry were processed according to the method of
Jackson and Warner [8].
Functional characterization of TH1 and TH2 type of T cells
was performed on heparinised venous blood according to
the method of Luty et al [9] with minor modifications.
Briefly, leukocyte rich plasma was prepared from 4 ml of
heparinised blood and lymphocyte count was adjusted to
3.6 × 105/200 μl. Cultures were stimulated with 10% phy-
tohemagglutinin [PHA-P (DIFCO)] in RPMI-1640
medium (Sigma) and without PHA-P (unstimulated).
Cultures were incubated for 20 hrs at 37°C in an atmos-
phere of 5% CO2. The samples were centrifuged at 2000BMC Infectious Diseases 2006, 6:65 http://www.biomedcentral.com/1471-2334/6/65
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rpm for 5 minutes and the supernatant stored at -70°C
until required for cytokine assay. Cytokines (IL-4, IL-10,
IL-12, IFN-γ) were estimated in the culture supernatants
by sandwich ELISA using reagents from Pharmingen,
(USA) as per manufacturer's instructions. Briefly, culture
supernatants were distributed in ELISA plates coated with
corresponding anti-cytokine antibodies. Corresponding
detector antibodies were used to detect cytokine anti-
cytokine complexes. The reaction was developed with
TMB in 0.1 M sodium acetate solutions and H2O2, OD
was recorded at 450 nm. The concentration of the
cytokines in culture supernatants were calculated from the
standard curve for each cytokine plotted on a log-log
paper. Functional characterization of B cells was done by
estimation of sequential levels of HBsAb by ELISA.
Phenotypic markers were studied at baseline (B) and 11
days after second (D) and the third (F) dose of vaccine.
Functional characterization of TH1 and TH2 subsets of T
helper cells and levels of HBsAbs were estimated at base-
line (B), before and 11 days after second (C & D) and
before and 11 days after the third (E & F) dose of vaccine.
The timing was selected to pick up the peak titers (Figure
1)
Results
Out of 27 patients with high CD4 count, 17 were males
and 10 were females and the age ranged between 22 to 45
years with mean age of 30 ± 6 years. Out of 13 patients
with low CD4 counts, 6 were males and 7 were females
and the age ranged between 18 – 50 years with mean age
of 32 ± 8 years. Of the 20 normal controls, 12 were males
and 8 were females and the age ranged between 18 – 45
years with mean age of 29 ± 7 years.
T helper (CD4
+) Lymphocytes
At base line, mean CD4
+lymphocyte counts were highest
in controls followed by patients with high CD4 counts and
those with low CD4 counts in that order (p < 0.01; Fig 2B;
Table 1). After the second and the third dose of vaccina-
tion, 92% and 81% of high CD4 group and 61% and 76%
of low CD4 group patients respectively, showed a statisti-
cally significant increase in the number of CD4
+ lym-
phocytes (Fig 2 and 3; Table 1).
Similarly, 65% and 85% of normal control subjects
showed an increase in the number of CD4+ lymphocytes
after the second and the third dose of vaccination. The
increase was however more impressive after the third dose
of vaccination (Fig 3, Table 1).
T Cytotoxic CD8
+ Lymphocytes
At baseline, patients showed a higher number of CD8
+
lymphocytes as compared to normal subjects (p < 0.01)
(Table 1). After HBV vaccination, those with high CD4
count showed a statistically significant increase in mean
CD8
+ lymphocytes after each dose of vaccination. While
patients with low CD4 count showed a statistically signifi-
cant increase only after the third dose. Normal controls
also showed increased mean of CD8+ lymphocytes after
third dose of vaccination. There was a gross inversion of
the CD4/CD8 ratio in patients before and after immuniza-
tion while in controls, the ratio was one. As CD4
+ and
CD8
+  lymphocytes increased after vaccination, as
Schematic representation of tests conducted with time schedule Figure 1
Schematic representation of tests conducted with time schedule.BMC Infectious Diseases 2006, 6:65 http://www.biomedcentral.com/1471-2334/6/65
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expected, CD3
+ lymphocytes also increased after HBV vac-
cination.
Natural Killer cells (NK cells)
Basal CD16+56+ NK cell number was significantly lower in
patients with low CD4
+ lymphocytes than in controls.
After vaccination, patients with high CD4
+ lymphocytes
showed no significant increase in number of NK cells
whereas patients with low CD4counts responded after the
last dose, (p < 0.05). In controls, the NK cells increased
significantly after each dose of vaccination (Table 1).
CD45RA
+ Naïve cells
At baseline, there was no statistically significant difference
in CD45RA
+ cells between controls and patients with high
CD4
+ lymphocytes. Patients with low CD4 counts showed
a lower number of CD45RA
+ naïve cells as compared to
controls and patients with high CD4 counts (p < 0.01).
After vaccination, patients with high CD4 counts showed
Comparative mean CD4 lymphocyte counts between the various groups Figure 3
Comparative mean CD4 lymphocyte counts between the various groups.
Flowcytometric analysis of CD4/CD8 lymphocytes in patient with low CD4 counts Figure 2
Flowcytometric analysis of CD4/CD8 lymphocytes in patient with low CD4 counts. FL 1 shows FITC labeled CD4
+ T lym-
phocytes. FL 2 shows PE labeled CD8




35% 55%BMC Infectious Diseases 2006, 6:65 http://www.biomedcentral.com/1471-2334/6/65
Page 5 of 10
(page number not for citation purposes)
a significant increase in CD45RA
+ naïve cells after each dose
of vaccination whereas patients with low CD4 counts and
normal control subjects showed increase in CD45RA
+ naïve
cells after the third dose of vaccination (Fig. 4, Table 1).
CD45RO
+ Memory cells
Memory cells are crucial in response to any immuniza-
tion. In this study, patients with high CD4 counts showed
a significantly higher number of CD45RO
+ memory cells at
baseline as compared to controls while patients with low
CD4 counts showed a lower number of memory cells but
the difference between both the patient groups was statis-
tically insignificant. Memory cells also increased after
immunization and were higher in HIV positive patients
although control subjects showed an early rise of memory
cells after vaccination (Table 1).
HBsAb titers
After vaccination, 40% of patients with high CD4 counts
formed antibodies at stage C (205 ± 613 mIU/ml; p >
0.05) but 77% of patients had statistically significant lev-
els of HBsAb at stage D i.e. 11 days after second dose
(1181 ± 2912 mIU/ml, p < 0.05). Subsequently 46% of
patients had transient lowering of HBsAb levels at stage E
(524 ± 1478 mIU/ml p > 0.05). After third dose of vacci-
nation at stage F, 100% of patients with high CD4 counts
showed statistically significant levels of HBsAb [8034 ±
14136 mIU/ml, p < 0.01, (Table 2)]. HBsAb, titers above
100 mIU/ml were considered significant.
In comparison, only 47% of patients who had a CD4
count of < 200/mm3 could form HBsAb titers above 100
mlU/ml. Thirty eight percent of patients could not form
antibodies at all, and 15% of patients showed HBsAb tit-
ers of < 20 mIU/ml. Thus only 47% of these patients were
responders, but with significantly lower HBsAb titers (462
± 814 mIU/ml; p < 0.5).
The response to vaccination was delayed in normal con-
trol subjects. This could be due to the different dosage
schedule in patients vs. controls, the former being vacci-
nated with a double dose. At stage E, 85% of controls
formed statistically significant levels of HBsAbs. At final
stage, 90% of normal control subjects were responders
and there was a striking rise of HBsAb after the last dose.
Although in controls 10% were non-responders com-
pared to patients with high CD4 counts where 100% of
patients responded, yet the mean peak titers (60000 mIU/
ml) were much higher in controls than in patients with
high CD4 counts (Table 2).
TH 2- Cytokine changes
Basal IL-4 levels were higher in HIV positive patients as
compared to IL-4 levels in controls. Although IL-4 levels
were higher in patients with high CD4  counts than
patients with low CD4 counts yet the difference was statis-
tically insignificant (p > 0.05) (Table 3). HBV vaccination
however failed to elicit adequate IL-4 in HIV positive
patients. In controls there was massive increase in IL-4 lev-
els after the first dose of vaccination and levels were much
higher at all four stages (C to F) compared to HIV positive
patients (Table 3).
Basal IL-10 levels were also significantly higher in normal
control subjects as compared to HIV positive patients and
even after vaccination, IL-10 levels remained significantly
Flowcytometric analysis of CD45RA
+ Naïve T cells in patient with low CD4 counts Figure 4
Flowcytometric analysis of CD45RA
+ Naïve T cells in patient with low CD4 counts. FL 1 shows FITC labeled CD45RA
+ naïve T 
lymphocytes. Note an increase of CD45RA + naïve T cells from 34% at stage B to 56% at stage D.
B D
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higher in control subjects as compared to HIV positive
patients (Table 3). HBV vaccination thus failed to elicit
adequate IL-4 or IL-10 stimulation in HIV infected
patients.
TH 1- Cytokine changes
Basal IL-12 levels were almost similar in control subjects
and HIV positive patients. After vaccination, all patients
showed delayed but significant increase in IL-12 levels
whereas in controls there was massive though transient
increase in IL-12 levels (Table 3).
Baseline IFN-γ levels were much higher in control subjects
as compared to HIV positive patients (p < 0.01) but the
difference in basal IFN-γ levels in patients with high and
low CD4 counts was insignificant. However after vaccina-
tion, levels increased significantly in patients after 6
months. In controls, no further increase of IFN-γ levels
could be registered. Yet levels were significantly higher
than in patients (Table 3).
Discussion
It is known that HIV infection may modify the natural his-
tory of HBV infection and HIV positive patients have
higher rate of HBV chronicity, higher HBV replication and
low rates of sero-conversion to anti-HBe and anti-HBs
[10,11]. Immunization of HIV positive asymptomatic
patients with HBV vaccine could thus protect them from
HBV infection and reduce morbidity significantly.
Table 2: Post vaccination sequential anti HBsAb titers in different groups
Stages Mean ± SD in group 1A 
patient
Mean ± SD in group 1B 
patients
Mean ± SD in group II normal 
controls
Baseline B 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
Before 2nd dose (C) 205 ± 613 1 ± 4 0.00 ± 0.00
After 2nd dose (D) 1181 ± 2912 26 ± 49 118 ± 397
Before 3rd dose (E) 524 ± 1478 40 ± 90 225 ± 317
After 3rd dose (F) 8834 ± 14136 462 ± 814 16906 ± 21301













Table 1: Pre and Post vaccination mean of phenotypic markers at various stages in different groups:
CD4 CD8 CD16+56 CD45RA CD 45RO
Group IA
Stage B 393 ± 137/mm3 1374 ± 477/mm3 292 ± 194/mm3 1237 ± 480/mm3 1320 ± 490 mm3
Stage D 526 ± 178/mm3 1580 ± 478/mm3 269 ± 139/mm3 1471 ± 435/mm3 1548 ± 502 mm3
Stage F 632 ± 235/mm3 1645 ± 408/mm3 302 ± 188/mm3 1719 ± 590/mm3 1727 ± 538 mm3
Statistical analysis B/D p < 0.01 B/D p < 0.05 B/D p > 0.05 B/D p < 0.01 B/D p < 0.01
B/Fp < 0.01 B/F p < 0.01 B/F p > 0.05 B/F p < 0.01 B/F p < 0.01
D/Fp < 0.01 D/F p > 0.05 D/F p > 0.05 D/Fp < 0.01 D/F p < 0.05
Group I B
Stage B 117 ± 47/mm3 1082 ± 828/mm3 170 ± 119/mm3 760 ± 299/mm3 1015 ± 660 mm3
Stage D 169 ± 111/mm3 1354 ± 1003/mm3 193 ± 124/mm3 908 ± 341/mm3 1125 ± 780 mm3
Stage F 248 ± 146/mm3 1609 ± 949/mm3 293 ± 239/mm3 1328 ± 662/mm3 1461 ± 799 mm3
Statistical analysis B/D p < 0.05 B/D p > 0.05 B/D p > 0.05 B/D p > 0.05 B/D p > 0.05
B/F p < 0.01 B/F p < 0.05 B/F p < 0.05 B/F p < 0.01 B/F p < 0.05
D/Fp < 0.01 D/Fp > 0.05 D/Fp > 0.05 D/Fp < 0.05 D/Fp < 0.01
Group II
Stage B 743 ± 208/mm3 756 ± 325/mm3 252 ± 121/mm3 1213 ± 467/mm3 1041 ± 398 mm3
Stage D 862 ± 263/mm3 865 ± 390/mm3 364 ± 190/mm3 1338 ± 624/mm3 1235 ± 303 mm3
Stage F 937 ± 183/mm3 954 ± 335/mm3 490 ± 304/mm3 1592 ± 418/mm3 1209 ± 256 mm3
Statistical analysis B/D p > 0.05 B/D p > 0.05 B/D p < 0.05 B/D p > 0.05 B/D p < 0.01
B/F p < 0.01 B/F p < 0.01 B/F p < 0.01 B/F p < 0.01 B/F p < 0.05
D/Fp > 0.01 D/Fp > 0.05 D/F p < 0.05 D/Fp < 0.05 D/Fp > 0.05BMC Infectious Diseases 2006, 6:65 http://www.biomedcentral.com/1471-2334/6/65
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T cell changes after HBV vaccination
Decreased absolute CD4
+ lymphocyte number, percentage
and decreased CD4: CD8 ratio occurs early during the
course of HIV infection and are predictors of disease pro-
gression [12]. We analyzed basal CD4
+ lymphocytes and
changes if any, in the number of CD4
+ lymphocytes after
HBV vaccination. The basal CD4
+ cell count in Indians
were found to be lower than Caucasians (743± 214).
Response to any vaccine is dependant on adequate func-
tion of CD4
+  helper cells. In the present study also,
response to HBV vaccination was directly correlated with
CD4
+ lymphocyte number. After the second dose of HBV
vaccination, 92% of patients with high CD4  counts,
showed a significant increase in the number of CD4
+ lym-
phocytes (peak of 1135/mm3) compared to only 61% of
patients with low CD4 counts (peak of 472/mm3). In con-
trol subjects, the increase was more impressive after the
third dose and peak levels were much higher (1531/
mm3). It is important to note that mean CD4
+  lym-
phocytes increased significantly after vaccination at each
stage irrespective of the disease status.
CD8
+ lymphocytes are responsible for eliminating virus
infected cells and act as a second line of defense by
becoming activated and eliminating any infected cell,
despite the presence of neutralizing antibodies [13]. They
can inhibit viral replication by secreting T lymphocyte
antiviral factor (CAF), which inhibits RNA transcription
[14]. However, there is a paucity of data regarding quali-
tative and quantitative changes in CD8
+ lymphocytes after
HBV immunization. In the present study, average number
of total circulating CD8
+ lymphocytes in control subjects
was 756/mm3, which is higher than the figures (500/
mm3) reported in Caucasians [12]. Mean value of CD8
+
cells was much higher in HIV positive patients. After
immunization CD8
+ T lymphocytes increased further in
all the groups. It has earlier been documented that HIV is
associated with a functional defect of CD8
+ cells. Wilson et
al [15] had reported that decreased responsiveness to HBV
vaccine in HIV infected subjects is associated with ele-
vated CD8
+ CD38
+ HLA DR+ T cells. In murine studies it has
been observed that repeated exposure to unrelated patho-
gens, as happens in HIV infected patients, may adversely
affect viral specific CD8
+ lymphocytes [16].
At baseline, CD4:CD8 ratio in normal control subjects was
approximately 1, which is also distinctly different from
the values reported in the west where the ratio is close to
two [12]. Our data corroborates the observation made by
Sehgal et al [17] who also documented a lower CD4
+ cell
number, a higher CD8
+ cell count and CD4:CD8 ratio of 1
in healthy North Indians.
Besides CD4
+ and CD8
+ cells, NK cells are key cells that
deal with virally infected cells. Majority of peripheral
blood lymphocytes that mediate NK cytotoxic activity in
healthy adults express both CD16 and CD56 . Using these
two NK cell markers, a decrease in NK cell number has
been reported in HIV infected individuals [18,19]. In the
present study too, the basal mean of NK cells were low in
immunosupressed patients compared to patients with
high CD4 counts and normal control subjects. After HBV
Table 3: Pre & Post-vaccination mean of IL-4, IL-10 and IFN-γ levels with PHA stimulation at various stages in different groups.
Stimulated mean ± SD pg/ml Statistical analysis
IL-4 Baseline (B) Before 2nd dose 
(C)
After 2nd dose (D) Before 3rd dose 
(E)
After 3rd dose (F)
Group IA 81 ± 82 95 ± 130 82 ± 55 70 ± 51 81 ± 92 B/C p > 0.05 B/D p > 0.05 B/E p > 
0.05 B/F p > 0.05
Group IB 63 ± 69 38 ± 29 48 ± 28 58 ± 62 87 ± 146 B/C p > 0.05 B/D p > 0.05 B/E p > 
0.05 B/F p > 0.05
Group II 41 ± 72 284 ± 232* 185 ± 159* 172 ± 151* 810 ± 203* B/C p < 0.01* B/D p < 0.01* B/E p 
< 0.01 * B/F p < 0.01*
IL-10
Group IA 162 ± 152 118 ± 94 155 ± 148 160 ± 184 188 ± 194 B/C p > 0.05 B/D p > 0.05 B/E p > 
0.05 B/F p > 0.05
Group IB 117 ± 141 70 ± 66 92 ± 75 138 ± 112 139 ± 99 B/C p > 0.05 B/D p > 0.05 B/E p > 
0.05 B/F p > 0.05
Group II 295 ± 151 365 ± 213 231 ± 223 229 ± 226* 302 ± 232* B/C p < 0.05* B/D p < 0.05* B/E p 
< 0.05 * B/F p < 0.05*
IFN-γ
Group IA 107 ± 106 125 ± 208 133 ± 173 246 ± 255* 274 ± 268* B/C p > 0.05 B/D p > 0.05 B/E p < 
0.01* B/F p < 0.01*
Group IB 72 ± 86 62 ± 131 39 ± 41 154 ± 221* 197 ± 285* B/C p > 0.05 B/D p > 0.05 D/E p 
< 0.05* D/F p < 0.05*
Group II 348 ± 216 408 ± 247 292 ± 236 409 ± 304 273 ± 213 B/C p > 0.05 B/D p > 0.05 B/E p > 
0.05 B/F p > 0.05BMC Infectious Diseases 2006, 6:65 http://www.biomedcentral.com/1471-2334/6/65
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vaccination, NK cells in controls increased after each dose
unlike in patients with high CD4 counts where no signifi-
cant difference was observed. Patients with low CD4
counts showed a significant increase only after the last
dose of vaccination (170 vs. 293/mm3 p < 0.05). The
present study thus illustrates that NK cell response is also
compromised in HIV/AIDS.
Naïve and memory T cells
In HIV infection, CD4
+ lymphocytes with the memory
phenotype harbor more HIV provirus and hence are can-
didates for depletion by HIV cytopathic effects following
activation and subsequent stimulation of viral replication
[20]. Although it was initially believed that phenotypi-
cally defined memory cells were selectively decreased in
HIV infected patients [21], subsequent studies showed
that there is no such decrease in the cell number yet a
functional impairment could be demonstrated. The exact
cause of this functional impairment is still elusive [22,23].
In the present study naïve cells were significantly lower in
patients with severe disease while the number of memory
cells was increased in HIV/AIDS patients. In spite of this,
HBsAb levels were lower than controls thus confirming a
functional defect.
Cytokine response
In our study, HIV infected vaccinated patients failed to
elicit adequate IL-4 response. IL4 and IL-10 are the two
key cytokines facilitating antibody response. Klein et al
[24] also demonstrated that increased IL-4 levels were
seen only in early stages of HIV infection. Similarly Kid et
al [25] and Romagnani et al [26] questioned the TH1/TH2
imbalance hypothesis and discussed its limitations. We
also observed a significant lowering of basal mean IL-10
levels in HIV infected patients compared to controls (p <
0.01). After vaccination, patients with advanced disease
showed a delayed and diminished response of IL-10. Thus
both IL-4 and IL-10 responses were suboptimal in HIV
positive patients, a finding at variance with that reported
by Clerici and Sheara [27]. Hong et al [28] and Fakoya et
al [29] also documented that TH2 cytokines were
increased in HIV infected subjects. Suboptimal responses
of both IL-4 and IL-10 observed with HIV patients could
have accounted for weak HBsAb titers in HIV infected
patients.
In the present study IFN-γ levels were much higher in con-
trols compared to both the groups of HIV infected
patients. Further, the response was delayed in patients and
the IFN-γ levels could not match the levels observed in
controls indicating a lack of T cell help. IL-12 levels are
documented to be low in plasma of HIV infected subjects
[30] but we could not document any significant difference
in IL-12 levels in different groups.
Our study illustrates that HBsAb titers were highest in
controls followed by seropositives and minimum in
patients with AIDS. Low CD4
+ lymphocytes and low TH2
type of cytokines i.e., IL-4, IL-10 which promote antibody
function and functionally abnormal memory cells possi-
bly accounted for low antibody titers in HIV infected
patients.
Diaz et al [31] stressed that the response to HBV vaccine
may be transitory in AIDS necessitating progressive mon-
itoring of HbsAbs. In a study conducted by Walch and
Morse [32], the response rate in patients with CD4 counts
of > 500/mm3 was 87% while the response rate dropped
to 33% in patients with a CD4 count between 200–500/
mm3. In our study only 6/40 patients had CD4 counts of
> 500/mm3, thus the response rate of 100% in our
patients with a CD4  count between 200–500/mm3  is
encouraging. These patients also gained weight and
depicted a rise of CD4
+ lymphocytes. The response rate in
controls receiving the conventional dose was 90%. Tedalli
et al [33] recommended that patients with a CD4 count of
< 200/mm3 should be treated with HAART first and HBV
vaccine given preferentially after the cut off of 200/mm3 is
achieved. This, however, is not possible in resource poor
countries. In an excellent comprehensive study on care of
patients with chronic HBV [34], the international panel
recommended that the antiHBs titers should be checked
12 weeks after immunization and booster given if the
response is sub optimal. A short statement of the first
European Consensus Conference on the treatment of
patients with HBV and HCV reiterates that all HIV patients
should be tested for viral hepatitis including those in
under served areas and vaccination/treatment offered as
and when necessary [35].
Conclusion
In our patients with low CD4 count, in spite of the double
dose of vaccine, only 47% were responders and with poor
titers against HBV and patients with CD4 counts of < 50/
mm3 did not respond at all. Thus early immunization is
advocated in all HIV positive patients at a stage when they
are still capable of mounting an adequate immune
response.
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